Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain.
Expert Rev Clin Immunol. 2011 Jul;7(4):491-8. doi: 10.1586/eci.11.39.
Systemic sclerosis (SSc) is a chronic systemic disease characterized by autoimmunity, vascular lesions and progressive fibrosis. The fibrotic component is dominant in SSc compared with other vascular or autoimmune diseases and determines its prognosis and therapeutic refractoriness. Fibroblasts are responsible for abnormal extracellular matrix accumulation. Studies in cultured SSc skin fibroblasts have facilitated the identification of potential pathways involved in their profibrotic phenotype. Profibrotic fibroblasts characterized by abnormal growth and extracellular matrix synthesis may differentiate or expand from normal resident fibroblasts. Recruitment of bone marrow-derived progenitors and transdifferentiation of different cell lineages might also be involved. Multiple factors and signaling pathways appear to be involved in the development or persistence of the SSc fibroblast phenotype. Although their relative relevance and interplay are unclear, aberrant TGF-β signaling seems pivotal and constitutes the best characterized therapeutic target.
系统性硬化症(SSc)是一种以自身免疫、血管病变和进行性纤维化为特征的慢性系统性疾病。与其他血管或自身免疫性疾病相比,纤维化成分在 SSc 中占主导地位,决定了其预后和治疗的难治性。成纤维细胞负责异常细胞外基质的积累。对培养的 SSc 皮肤成纤维细胞的研究促进了鉴定其致纤维化表型相关的潜在途径。异常生长和细胞外基质合成的致纤维化成纤维细胞可能来源于正常的驻留成纤维细胞分化或扩增。招募骨髓源性祖细胞和不同细胞谱系的转分化也可能涉及其中。多种因素和信号通路似乎参与了 SSc 成纤维细胞表型的发展或持续存在。尽管它们的相对相关性和相互作用尚不清楚,但异常的 TGF-β 信号似乎至关重要,并且是最具特征性的治疗靶点。